| Literature DB >> 28852714 |
Mluleki Luvuno1, Hlengiwe Prosperity Mbongwa1, Andile Khathi1.
Abstract
BACKGROUND: Diabetic polyphagia has been associated with elevated plasma ghrelin levels in experimental type 1 diabetes. This increase in food consumption contributes to chronic hyperglycaemia in diabetes thus contributing to the development of micro- and macrovascular complications. We have reported that plant-derived oleanolic acid (OA) and maslinic acid (MA) reduce blood glucose levels, in part, through the inhibition of intestinal carbohydrate hydrolyzing enzymes and glucose transporters. However, their effects on food intake and plasma ghrelin concentrations are unclear. Accordingly, we investigated the effects of these triterpenes on food intake and ghrelin expression in streptozotocin-induced diabetic rats. MATERIAL: The effects of OA and MA on blood glucose concentration; food and water intake were monitored over five weeks after which plasma ghrelin concentrations were measured. Additionally, the expression of ghrelin in the various sections of the GIT was determined using Western blot analysis.Entities:
Keywords: Syzygium aromaticum; diabetes mellitus; ghrelin; maslinic acid; oleanolic acid; triterpenes
Mesh:
Substances:
Year: 2016 PMID: 28852714 PMCID: PMC5566155 DOI: 10.21010/ajtcam.v13i4.2
Source DB: PubMed Journal: Afr J Tradit Complement Altern Med ISSN: 2505-0044
Comparison of 13C Bruker NMR spectra of S. aromaticum-derived OA and MA with that reported by Martinez et al., 2013 and Juli et al., 2003 respectively.
| Carbon number | OA | MA | ||
|---|---|---|---|---|
| Reported (Martinez et al., 2013) | Reported (Júlio et al., 2003) | |||
| 1 | 39.9 | 39.9 | 46.2 | 46.4 |
| 2 | 27.9 | 27.5 | 68.3 | 68.8 |
| 3 | 79.7 | 79.5 | 83.3 | 83.7 |
| 4 | 39.3 | 39.3 | 39.1 | 39.1 |
| 5 | 56.8 | 56.8 | 55.0 | 55.5 |
| 6 | 19.5 | 19.5 | 18.1 | 18.5 |
| 7 | 33.8 | 33.8 | 32.7 | 32.5 |
| 8 | 40.6 | 40.5 | 39.0 | 39.1 |
| 9 | 49.1 | 49.1 | 47.4 | 47.5 |
| 10 | 38.2 | 38.2 | 38.0 | 38.1 |
| 11 | 24.5 | 24.5 | 23.2 | 23.2 |
| 12 | 123.7 | 123.5 | 121.9 | 121.9 |
| 13 | 145.2 | 145.2 | 143.7 | 143.7 |
| 14 | 42.9 | 42.8 | 41.6 | 41.8 |
| 15 | 28.9 | 28.8 | 27.4 | 27.5 |
| 16 | 24.1 | 24.1 | 23.0 | 23.3 |
| 17 | 47.6 | 47.4 | 46.2 | 46.6 |
| 18 | 42.8 | 42.8 | 41.0 | 41.3 |
| 19 | 47.3 | 47.1 | 45.7 | 45.8 |
| 20 | 31.6 | 31.6 | 30.4 | 30.7 |
| 21 | 34.9 | 34.6 | 33.6 | 33.9 |
| 22 | 34 | 34.1 | 32.3 | 32.3 |
| 23 | 28.8 | 28.6 | 28.3 | 28.8 |
| 24 | 16.3 | 16.3 | 16.6 | 16.9 |
| 25 | 15.9 | 15.9 | 16.5 | 16.9 |
| 26 | 17.7 | 17.3 | 16.4 | 16.9 |
| 27 | 26.4 | 26.4 | 23.2 | 23.5 |
| 28 | 180.8 | 180.1 | 178.5 | 178.1 |
| 29 | 33.6 | 33.4 | 32.2 | 33.2 |
| 30 | 24 | 24 | 23.2 | 23.5 |
Comparison of the effects of OA and MA administered in STZ-diabetic rats twice every third day for 5 weeks on terminal blood glucose concentrations, plasma insulin and ghrelin concentrations with untreated STZ-diabetic rats. Values are presented as means, and vertical bars indicate SEM of means (n = 6 in each group)._
| Terminal blood glucose (mmol/L) | Plasma insulin (pmol/L) | Plasma ghrelin (pmol/L) | |
|---|---|---|---|
| Non-diabetic | 5.46 ± 0.83 | 9.37 ± 0.86 | 1.99 ± 0.07 |
| STZ-diabetic | 26.95 ± 2.00[ | 2.30 ± 0.74[ | 3.42 ± 0.17[ |
| STZ-OA treated | 7.54 ± 1.10 | 2.35 ± 0.84[ | 1.96 ± 0.11 |
| STZ-MA treated | 8.35 ± 2.00 | 2.36 ± 0.79[ | 2.44 ± 0.10 |
| STZ-Metformin treated | 7.68 ± 1.15 | 2.34 ± 0.77[ | 2.34 ± 0.14 |
| STZ-Insulin treated | 6.45 ± 1.27 | 2.37 ± 0.43[ | 1.91 ± 0.15 |
= p<0.05 by comparison to the non-diabetic control.
= p<0.05 by comparison to the STZ-induced diabetic control